Drug General Information |
Drug ID |
D0I7IB
|
Former ID |
DCL001100
|
Drug Name |
Sodium butyrate
|
Synonyms |
Butyrate sodium; Butyric acid sodium salt; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Butyric acid, sodium salt; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)
|
Drug Type |
Small molecular drug
|
Indication |
Acute myeloid leukemia; Refractory sickle cell ulcers [ICD9: 205, 282.5, 282.6; ICD10:C92.0, D57]
|
Phase 2 |
[1]
|
Company |
Allerderm
|
Structure |
|
Download
2D MOL
3D MOL
|
Formula |
C4H7NaO2
|
Canonical SMILES |
CCCC(=O)[O-].[Na+]
|
InChI |
1S/C4H8O2.Na/c1-2-3-4(5)6;/h2-3H2,1H3,(H,5,6);/q;+1/p-1
|
InChIKey |
MFBOGIVSZKQAPD-UHFFFAOYSA-M
|
CAS Number |
CAS 156-54-7
|
PubChem Compound ID |
|
PubChem Substance ID |
3140473, 7772599, 8137204, 8600423, 10509278, 12014931, 15297044, 24858121, 24891873, 26759539, 29227696, 49898106, 56311077, 56311464, 56312142, 56312587, 56313371, 56314083, 57357512, 80709488, 80709489, 84942898, 85736426, 87559080, 88813254, 96021279, 96025681, 99374859, 103256603, 103849246, 104253446, 107598695, 113834572, 117375108, 117687779, 118052709, 124757572, 125164376, 125333742, 125364413, 126688146, 127331465, 127331466, 127331467, 127331468, 127331469, 127331470, 127331471, 134974438, 135610560
|
Target and Pathway |
Target(s) |
Histone deacetylase 1 |
Target Info |
Inhibitor |
[2],
[3]
|
KEGG Pathway
|
Cell cycle
|
Notch signaling pathway
|
Thyroid hormone signaling pathway
|
Huntington's disease
|
Amphetamine addiction
|
Alcoholism
|
Epstein-Barr virus infection
|
Pathways in cancer
|
Transcriptional misregulation in cancer
|
Viral carcinogenesis
|
MicroRNAs in cancer
|
Chronic myeloid leukemia
|
NetPath Pathway
|
TCR Signaling Pathway
|
PANTHER Pathway
|
Wnt signaling pathway
|
p53 pathway
|
Pathway Interaction Database
|
Regulation of nuclear SMAD2/3 signaling
|
Notch signaling pathway
|
E2F transcription factor network
|
Presenilin action in Notch and Wnt signaling
|
Signaling events mediated by HDAC Class I
|
Regulation of Telomerase
|
Glucocorticoid receptor regulatory network
|
Sumoylation by RanBP2 regulates transcriptional repression
|
Regulation of Androgen receptor activity
|
IL3-mediated signaling events
|
Validated nuclear estrogen receptor alpha network
|
Retinoic acid receptors-mediated signaling
|
Hedgehog signaling events mediated by Gli proteins
|
Regulation of nuclear beta catenin signaling and target gene transcription
|
Validated targets of C-MYC transcriptional repression
|
Regulation of retinoblastoma protein
|
Notch-mediated HES/HEY network
|
Reactome
|
G0 and Early G1
|
p75NTR negatively regulates cell cycle via SC1
|
Formation of the beta-catenin:TCF transactivating complex
|
NOTCH1 Intracellular Domain Regulates Transcription
|
SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
|
Constitutive Signaling by NOTCH1 PEST Domain Mutants
|
Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
|
HDACs deacetylate histones
|
Deactivation of the beta-catenin transactivating complex
|
NoRC negatively regulates rRNA expression
|
RNA Polymerase I Transcription Initiation
|
Factors involved in megakaryocyte development and platelet production
|
WikiPathways
|
SIDS Susceptibility Pathways
|
Notch Signaling Pathway
|
TGF beta Signaling Pathway
|
IL-6 signaling pathway
|
Apoptosis-related network due to altered Notch3 in ovarian cancer
|
Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
|
Notch Signaling Pathway
|
Retinoblastoma (RB) in Cancer
|
Neural Crest Differentiation
|
TWEAK Signaling Pathway
|
Integrated Breast Cancer Pathway
|
Signalling by NGF
|
RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription
|
Mitotic G1-G1/S phases
|
Factors involved in megakaryocyte development and platelet production
|
Cell Cycle
|
Androgen receptor signaling pathway
|
References |
REF 1 | The enhancement of phase 2 enzyme activities by sodium butyrate in normal intestinal epithelial cells is associated with Nrf2 and p53. Mol Cell Biochem. 2012 Nov;370(1-2):7-14. |
---|
REF 2 | Two histone deacetylase inhibitors, trichostatin A and sodium butyrate, suppress differentiation into osteoclasts but not into macrophages. Blood. 2003 May 1;101(9):3451-9. Epub 2003 Jan 2. |
---|
REF 3 | Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006 Sep;5(9):769-84. |